Cargando…
Liposomal amphotericin B—the present
Most invasive fungal infections are opportunistic in nature but the epidemiology is constantly changing, with new risk groups being identified. Neutropenia is a classical risk factor for fungal infections, while critically ill patients in the ICU are now increasingly at risk of yeast and mould infec...
Autores principales: | Maertens, J, Pagano, L, Azoulay, E, Warris, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693760/ https://www.ncbi.nlm.nih.gov/pubmed/36426672 http://dx.doi.org/10.1093/jac/dkac352 |
Ejemplares similares
-
Liposomal amphotericin B—the future
por: Hoenigl, M, et al.
Publicado: (2022) -
Liposomal amphotericin B—the past
por: Brüggemann, R J, et al.
Publicado: (2022) -
Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B
por: Groll, Andreas H, et al.
Publicado: (2019) -
Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B
por: Adler-Moore, Jill, et al.
Publicado: (2019) -
Pharmacology of Liposomal Amphotericin B: An Introduction to Preclinical and Clinical Advances for Treatment of Life-threatening Invasive Fungal Infections
por: Walsh, Thomas J, et al.
Publicado: (2019)